Stimulator of interferon genes (STING) links innate immunity to biological processes ranging
from antitumor immunity to microbiome homeostasis. Mechanistic understanding of the …

Type I interferon (IFN), essential for spontaneous T cell priming against solid tumors, is
generated through recognition of tumor DNA by STING. Interestingly, we observe that type I …

Activation of the stimulator of interferon gene (STING) pathway within the tumor
microenvironment has been shown to generate a strong antitumor response. Although local …

The clinical utility of stimulator of interferon genes (STING) agonists has been limited due to
poor tumour-targeting and unwanted toxicity following systemic delivery. Here we describe a …

Cancer immunotherapy with immune checkpoint inhibitors has achieved unprecedented
success in cancer treatment; However, only a subset of patients achieved clinical benefit …

Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have
been effective in only a small subset of patients and a principal mechanism underlying …

Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

Cyclic dinucleotide (CDN) agonists of the STimulator of InterferoN Genes (STING) pathway
have shown immune activation and tumor clearance in pre-clinical models. However, CDNs …

Detection of cytosolic DNA by the enzyme cGAS triggers the production of cGAMP, a second
messenger that binds and activates the adaptor protein STING, which leads to interferon …

Solid cancers are able to escape immune surveillance and are resistant to current treatment
in immunotherapy. Recent evidence indicates the critical role of the stimulator of interferon …